Company intelligence / Profile preview

Genprex, Inc.

Austin, Texas, United Statesgenprex.com ↗
Ownership
Public · GNPX
Development stage
Other
01

Overview

The company has demonstrated clinical achievement in Phase 1 and Phase 2 studies for its cancer therapies. Its diabetes gene therapy has shown ability to stabilize glucose levels and reduce insulin requirements in non-human primate studies[5].

Therapeutic areas
OncologyEndocrinology
Modalities
Gene therapynon-viral gene therapyAAV vector gene therapy
Industry
Biotech
02

Drug pipeline

7 assets

quaratusugene ozeplasmid

2

6 more assets in the full pipeline.

03

Financials

Market cap
$1.1M
Total revenue
$0
Enterprise value
$-14.1M

Beyond the preview

Go deeper on Genprex, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genprex, Inc..

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call